Hydrochlorothiazide and spironolactone and Verteporfin Intravenous, Injection
Determining the interaction of Hydrochlorothiazide and spironolactone and Verteporfin Intravenous, Injection and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Concomitant use of verteporfin with other known photosensitizing agents may increase the risk of photosensitivity reactions. Medicinal products with known phototoxic or photoallergic potential include fluoroquinolones, phenothiazines, retinoids, sulfonamides, sulfonylureas, tetracyclines, thiazide diuretics, griseofulvin, and hypericin extracts (e.g., St John's Wort). MANAGEMENT: Caution is advised and pharmacologic response to photodynamic therapy should be carefully monitored if concomitant use of other photosensitizing agents cannot be avoided. Patients should be advised to avoid exposure of skin or eyes to sunlight or bright indoor lights (e.g., examination lamps, operating room lamps, tanning beds, lights at close proximity) for 5 days after administration of verteporfin. References Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0 "Multum Information Services, Inc. Expert Review Panel" "Product Information. Visudyne (verteporfin)" Valeant Pharmaceuticals, Costa Mesa, CA.
Professional:MONITOR: Concomitant use of verteporfin with other known photosensitizing agents may increase the risk of photosensitivity reactions. Medicinal products with known phototoxic or photoallergic potential include fluoroquinolones, phenothiazines, retinoids, sulfonamides, sulfonylureas, tetracyclines, thiazide diuretics, griseofulvin, and hypericin extracts (e.g., St John's Wort).
MANAGEMENT: Caution is advised and pharmacologic response to photodynamic therapy should be carefully monitored if concomitant use of other photosensitizing agents cannot be avoided. Patients should be advised to avoid exposure of skin or eyes to sunlight or bright indoor lights (e.g., examination lamps, operating room lamps, tanning beds, lights at close proximity) for 5 days after administration of verteporfin.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- "Multum Information Services, Inc. Expert Review Panel"
- "Product Information. Visudyne (verteporfin)" Valeant Pharmaceuticals, Costa Mesa, CA.
Generic Name: hydrochlorothiazide / spironolactone
Brand name: Aldactazide
Synonyms: Hydrochlorothiazide and Spironolactone
Generic Name: verteporfin
Brand name: Visudyne
Synonyms: Verteporfin
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Hydrochlorothiazide and spironolactone-Verzenio
- Hydrochlorothiazide and spironolactone-Vesanoid
- Hydrochlorothiazide and spironolactone-VESIcare
- Hydrochlorothiazide and spironolactone-Vestura
- Hydrochlorothiazide and spironolactone-Vet One Silver Nitrate
- Hydrochlorothiazide and spironolactone-Vexol
- Verteporfin Intravenous, Injection-Hydrochlorothiazide and telmisartan
- Verteporfin Intravenous, Injection-Hydrochlorothiazide and triamterene
- Verteporfin Intravenous, Injection-Hydrochlorothiazide and valsartan
- Verteporfin Intravenous, Injection-Hydrochlorothiazide Capsules
- Verteporfin Intravenous, Injection-Hydrochlorothiazide Tablets
- Verteporfin Intravenous, Injection-Hydrocil